Geovax Labs, INC S-1 registration statements

GeoVax Labs, Inc. has filed a registration statement for the resale of up to 7,639,967 shares of its common stock by selling stockholders.

GeoVax Labs, a clinical-stage biotechnology company, is offering up to $7.5 million in common and pre-funded units to fund operations, facing a 'going concern' opinion and recent contract termination.

GeoVax Labs files an S-1 registration statement for warrant resale, highlighting clinical advancements in vaccines and oncology therapies while facing significant financial challenges and a 'going concern' opinion.

GeoVax Labs, a clinical-stage biotechnology company, has filed an S-1/A registration statement for a public offering of up to 8,333,334 common units and pre-funded units to raise approximately $6.8 million, aiming to fund its vaccine and immunotherapy programs despite a history of operating losses and a recent contract termination.

GeoVax Labs, a clinical-stage biotechnology company, announced a public offering of up to $7.5 million in units to fund its vaccine and immunotherapy pipeline, while also disclosing the termination of a significant BARDA contract for its COVID-19 vaccine.

GeoVax Labs files an S-1 registration statement for the resale of up to 975,610 shares of common stock by a selling stockholder, derived from a recent private placement.

GeoVax Labs files an S-1 registration for the resale of up to 1.7 million shares of its common stock, potentially generating proceeds for the selling stockholder upon warrant exercise.

GeoVax Labs files an S-1 registration statement for the resale of up to 2.17 million shares of common stock by a selling stockholder, aiming to bolster working capital and general corporate purposes.

GeoVax Labs has filed a registration statement for the resale of up to 1,605,688 shares of its common stock, issuable upon the exercise of warrants from a recent private placement.